With the exception of a few monogenic forms, Alzheimer disease (AD) has a complex
aetiology that is likely to involve multiple susceptibility genes and environmental factors. The …

Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of
late-onset Alzheimer disease (AD), with the APOE* ε 4 allele conferring an increased risk …

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive
memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its …

Cerebrospinal fluid (CSF) amyloid-β peptide (Aβ) 42/Aβ40 and the concentration of tau
phosphorylated at site 181 (p-tau181) are well-established biomarkers of Alzheimer's …

Objective We examined whether plasma β-amyloid (Aβ) 42/Aβ40, as measured by a high-
precision assay, accurately diagnosed brain amyloidosis using amyloid PET or CSF p …

The search for the genetic factors contributing to Alzheimer disease (AD) has evolved
tremendously throughout the years. It started from the discovery of fully penetrant mutations …

Alzheimer's disease (AD) is the most common neurodegenerative disease among the
elderly with a progressive decline in cognitive function significantly affecting quality of life …

The first description of Alzheimer's disease (AD) was made in 1907 by Alois Alzheimer
(Allgemeine Zeitschrift fur Psyciatrie und Psychisch‐Gerichtliche Medizin 64, 3, 1907) …

Alzheimer's disease (AD) is a progressive, neurodegenerative disease and the most
common form of dementia in elderly people. It is an emerging public health problem that …

As the discovery of the Alzheimer's disease (AD) genes, APP, PSEN1, and PSEN2, in
families with autosomal dominant early-onset AD (EOAD), gene discovery in familial EOAD …